newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass., Aug. 8, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NA